(IOSP) Innospec - Ratings and Ratios
Fuel Additives, Oilfield Chemicals, Octane Boosters, Specialty Surfactants
IOSP EPS (Earnings per Share)
IOSP Revenue
Description: IOSP Innospec
Innospec Inc (NASDAQ:IOSP) is a US-based company operating in the Specialty Chemicals sub-industry. To evaluate its investment potential, we need to deconstruct its financial performance and identify key drivers.
The companys income tax expense is a critical component of its financials, impacting its net income. A thorough analysis of this aspect is essential to understanding its profitability. We should examine the trend of income tax expense over time, its proportion to pre-tax income, and how it affects the companys overall tax rate.
From a fundamental perspective, Innospecs market capitalization stands at approximately $1.98 billion, with a forward P/E ratio of 14.35, indicating the markets expectations for future earnings growth. The return on equity (RoE) is relatively low at 2.20%, suggesting that the company may not be generating sufficient profits from shareholders equity. Key performance indicators (KPIs) such as revenue growth, gross margin, and operating cash flow margin should be analyzed to understand the underlying drivers of the companys financial performance.
Economic drivers that may impact Innospecs business include fluctuations in raw material prices, changes in demand for its specialty chemicals products, and the competitive landscape within the industry. The companys exposure to various end-markets, such as automotive, oil and gas, and personal care, can also influence its financial performance. A detailed analysis of these factors is necessary to assess the companys potential for long-term growth and profitability.
To make informed investment decisions, it is crucial to evaluate Innospecs financial health, managements effectiveness, and the industrys outlook. By examining key metrics such as debt-to-equity ratio, interest coverage, and return on assets (RoA), we can gain a more comprehensive understanding of the companys financial position and its ability to generate returns for shareholders.
IOSP Stock Overview
| Market Cap in USD | 2,060m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1998-05-13 |
IOSP Stock Ratings
| Growth Rating | -13.5% |
| Fundamental | 47.0% |
| Dividend Rating | 56.7% |
| Return 12m vs S&P 500 | -33.2% |
| Analyst Rating | 4.50 of 5 |
IOSP Dividends
| Dividend Yield 12m | 1.74% |
| Yield on Cost 5y | 2.33% |
| Annual Growth 5y | 8.31% |
| Payout Consistency | 80.1% |
| Payout Ratio | 30.0% |
IOSP Growth Ratios
| Growth Correlation 3m | -27.6% |
| Growth Correlation 12m | -84.5% |
| Growth Correlation 5y | 53.6% |
| CAGR 5y | 4.63% |
| CAGR/Max DD 5y | 0.12 |
| Sharpe Ratio 12m | -0.14 |
| Alpha | -39.38 |
| Beta | 1.099 |
| Volatility | 24.68% |
| Current Volume | 124.8k |
| Average Volume 20d | 177.6k |
| Stop Loss | 84.9 (-3.1%) |
| Signal | -0.90 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (19.3m TTM) > 0 and > 6% of Revenue (6% = 107.4m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -4.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.31% (prev 28.72%; Δ 6.59pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 137.1m > Net Income 19.3m (YES >=105%, WARN >=100%) |
| Net Debt (-217.3m) to EBITDA (161.2m) ratio: -1.35 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (25.1m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 28.40% (prev 30.39%; Δ -1.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 102.1% (prev 111.4%; Δ -9.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 6.82
| (A) 0.35 = (Total Current Assets 969.7m - Total Current Liabilities 337.4m) / Total Assets 1.81b |
| (B) 0.59 = Retained Earnings (Balance) 1.06b / Total Assets 1.81b |
| (C) 0.07 = EBIT TTM 123.5m / Avg Total Assets 1.75b |
| (D) 2.04 = Book Value of Equity 1.03b / Total Liabilities 504.6m |
| Total Rating: 6.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.95
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 4.19% = 2.10 |
| 3. FCF Margin 4.62% = 1.16 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda 1.13 = 1.57 |
| 6. ROIC - WACC -0.80% = -1.00 |
| 7. RoE 1.54% = 0.13 |
| 8. Rev. Trend -82.80% = -4.14 |
| 9. Rev. CAGR -5.45% = -0.91 |
| 10. EPS Trend -34.08% = -0.85 |
| 11. EPS CAGR -16.75% = -2.09 |
What is the price of IOSP shares?
Over the past week, the price has changed by +0.54%, over one month by +6.75%, over three months by +1.73% and over the past year by -21.87%.
Is Innospec a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IOSP is around 78.22 USD . This means that IOSP is currently overvalued and has a potential downside of -10.7%.
Is IOSP a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IOSP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 115 | 31.3% |
| Analysts Target Price | 115 | 31.3% |
| ValueRay Target Price | 87.9 | 0.3% |
Last update: 2025-08-19 02:48
IOSP Fundamental Data Overview
CCE Cash And Equivalents = 266.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 107.7143
P/E Forward = 15.5039
P/S = 1.1502
P/B = 1.59
P/EG = -2.95
Beta = 1.051
Revenue TTM = 1.79b USD
EBIT TTM = 123.5m USD
EBITDA TTM = 161.2m USD
Long Term Debt = 167.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 15.6m USD (from shortTermDebt, last quarter)
Debt = 182.8m USD (Calculated: Short Term 15.6m + Long Term 167.2m)
Net Debt = -217.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.98b USD (2.06b + Debt 182.8m - CCE 266.6m)
Interest Coverage Ratio = unknown (Ebit TTM 123.5m / Interest Expense TTM 0.0)
FCF Yield = 4.19% (FCF TTM 82.8m / Enterprise Value 1.98b)
FCF Margin = 4.62% (FCF TTM 82.8m / Revenue TTM 1.79b)
Net Margin = 1.08% (Net Income TTM 19.3m / Revenue TTM 1.79b)
Gross Margin = 28.40% ((Revenue TTM 1.79b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Tobins Q-Ratio = 1.92 (Enterprise Value 1.98b / Book Value Of Equity 1.03b)
Interest Expense / Debt = 1.15% (Interest Expense 2.10m / Debt 182.8m)
Taxrate = 13.59% (from yearly Income Tax Expense: 5.60m / 41.2m)
NOPAT = 106.7m (EBIT 123.5m * (1 - 13.59%))
Current Ratio = 2.87 (Total Current Assets 969.7m / Total Current Liabilities 337.4m)
Debt / Equity = 0.14 (Debt 182.8m / last Quarter total Stockholder Equity 1.30b)
Debt / EBITDA = 1.13 (Net Debt -217.3m / EBITDA 161.2m)
Debt / FCF = 2.21 (Debt 182.8m / FCF TTM 82.8m)
Total Stockholder Equity = 1.25b (last 4 quarters mean)
RoA = 1.07% (Net Income 19.3m, Total Assets 1.81b )
RoE = 1.54% (Net Income TTM 19.3m / Total Stockholder Equity 1.25b)
RoCE = 8.70% (Ebit 123.5m / (Equity 1.25b + L.T.Debt 167.2m))
RoIC = 8.52% (NOPAT 106.7m / Invested Capital 1.25b)
WACC = 9.32% (E(2.06b)/V(2.24b) * Re(10.06%)) + (D(182.8m)/V(2.24b) * Rd(1.15%) * (1-Tc(0.14)))
Shares Correlation 5-Years: 70.0 | Cagr: 0.21%
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.84% ; FCFE base≈108.8m ; Y1≈112.5m ; Y5≈127.4m
Fair Price DCF = 64.49 (DCF Value 1.60b / Shares Outstanding 24.8m; 5y FCF grow 3.39% → 3.0% )
Revenue Correlation: -82.80 | Revenue CAGR: -5.45%
Rev Growth-of-Growth: 1.14
EPS Correlation: -34.08 | EPS CAGR: -16.75%
EPS Growth-of-Growth: -57.27
Additional Sources for IOSP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle